TCR (T-cell receptor) and CAR (chimeric antigen receptor) are two different ways to engineer immune cells to fight cancer. The core difference: a TCR recognizes fragments of proteins displayed on a cell’s surface through a natural presentation system, while a CAR uses an antibody-like structure to grab onto proteins sitting directly on the outside of a cell. This distinction shapes everything about how each therapy works, which cancers it can treat, and what side effects it causes.
How Each Receptor Finds Its Target
The TCR is the natural receptor that T cells already use. It works through a system called MHC (major histocompatibility complex), where cells constantly chop up their internal proteins into small fragments and display them on their surface like a molecular ID badge. The TCR scans these fragments, and if it spots something abnormal, it triggers an attack. In TCR-based therapy, a patient’s T cells are engineered with a specific TCR that recognizes a known cancer-related fragment.
A CAR is entirely synthetic. It bolts an antibody fragment (called an scFv) onto a signaling tail that activates the T cell. Because it uses an antibody to bind, a CAR latches directly onto whole proteins on the surface of cancer cells, skipping the MHC presentation system entirely. This MHC-independent approach means CAR-T cells can target anything on a cell’s exterior, as long as an antibody for that target exists.
What Each Therapy Can Target
This is where the practical implications get significant. The vast majority of a cell’s proteins are inside the cell, not on its surface. Because TCRs recognize fragments of internal proteins that get displayed through MHC, they can effectively “see” the full range of what’s happening inside a cancer cell. That includes mutated proteins, abnormal developmental proteins, and other markers that never appear on the cell surface in their whole form.
CARs are limited to proteins already sitting on the outside of the cell. They cannot detect anything happening internally. For blood cancers like certain leukemias and lymphomas, this works well because those cancer cells carry reliable surface markers (CD19 being the most well-known). For solid tumors, the surface targets are less consistent. Tumor cells in a solid mass often vary in which surface proteins they express, and some downregulate those proteins over time, essentially going invisible to CAR-T cells.
TCR-T cells have a theoretical advantage in solid tumors precisely because they can target intracellular proteins like cancer-testis antigens (NY-ESO-1, MAGE-A4) and neoantigens created by the specific mutations driving a patient’s tumor. These targets are more consistently present and harder for the cancer to shed.
Sensitivity to Low Levels of Antigen
One of the most striking differences is how little antigen each receptor needs to activate. A natural TCR can trigger a full T-cell response after detecting as few as 1 to 10 target molecules on a cell’s surface. CARs, by contrast, need thousands of target molecules to generate a comparable signal. TCRs are at least 100-fold more sensitive.
Paradoxically, CARs actually bind their targets much more tightly than TCRs do. TCRs bind with micromolar affinity (relatively loose), while CARs bind with nanomolar affinity (much tighter). But this tighter grip appears to work against the CAR. A looser-binding TCR can release and re-engage rapidly, scanning many targets in quick succession, a process called serial triggering. The CAR’s tight hold slows this process down, meaning it needs more targets available simultaneously to reach the activation threshold.
HLA Matching: A Major Practical Hurdle
Because TCRs work through the MHC system, which is encoded by a person’s HLA genes, TCR-T therapy requires HLA matching. A TCR engineered to recognize a cancer fragment presented by one HLA type simply won’t work in a patient with a different HLA type. This limits which patients qualify for any given TCR-T product and means that TCRs developed using one population’s common HLA types may not be applicable elsewhere.
CAR-T cells sidestep this problem entirely. Since the CAR binds directly to surface proteins without involving MHC, any patient whose tumor expresses the target protein is a potential candidate, regardless of their HLA type. This makes CAR-T therapy far simpler to develop as a broadly applicable product.
Intensity of Response and Toxicity
CAR-T cells hit harder and faster. In lab comparisons using the same target, CAR-T cells produced higher levels of inflammatory signaling molecules and killed cancer cells more efficiently in the short term. But that intensity comes with costs. Cytokine release syndrome, a potentially dangerous inflammatory reaction, and neurotoxicity are frequent complications of CAR-T therapy.
TCR-engineered T cells produce a more measured response. They release lower amounts of inflammatory molecules when encountering the same amount of tumor. While it’s not fully established how this translates to clinical outcomes, the lower cytokine output suggests milder treatment-related side effects. TCR-T cells also showed lower levels of exhaustion markers (PD-1 and LAG-3) after repeated exposure to tumor cells, with CAR-T cells expressing roughly threefold higher levels of LAG-3. This matters because exhaustion is one of the main reasons engineered T cells stop working over time.
The flip side of CAR-T cells’ aggressive response is that they were significantly more prone to activation-induced cell death. After overnight exposure to tumor cells, fewer CAR-T cells survived compared to TCR-T cells. A therapy that burns bright but burns out quickly may struggle with durable long-term control.
Where Each Therapy Stands Clinically
CAR-T therapy is far ahead in approvals and clinical use. Multiple CAR-T products are FDA-approved for blood cancers, including certain types of lymphoma, leukemia, and multiple myeloma. These therapies have produced remarkable response rates in cancers that previously had few options.
TCR-T therapy reached its first FDA approval more recently with afamitresgene autoleucel (Tecelra), developed by Adaptimmune. The field is newer, partly because TCR-T development is inherently more complex: each product must be matched to specific HLA types, and identifying the right intracellular targets requires extensive validation.
Both approaches face significant challenges in solid tumors. The immunosuppressive environment within solid tumors, poor T-cell infiltration, and antigen loss all limit effectiveness. But TCR-T cells are widely considered more promising for solid tumors because of their ability to target intracellular antigens and their greater sensitivity to low antigen levels. CAR-T therapy continues to dominate in blood cancers where reliable surface targets are abundant and the tumor microenvironment is less hostile.
Quick Comparison
- Target type: TCR targets fragments of internal proteins presented by MHC. CAR targets whole proteins on the cell surface.
- MHC dependence: TCR requires HLA matching. CAR works independently of MHC.
- Sensitivity: TCR activates with 1 to 10 antigen molecules. CAR needs thousands.
- Binding strength: TCR binds loosely (micromolar). CAR binds tightly (nanomolar).
- Cytokine production: CAR-T cells release more inflammatory molecules, linked to higher toxicity risk.
- Exhaustion: CAR-T cells show higher exhaustion markers after repeated antigen exposure.
- Best current fit: CAR-T for blood cancers. TCR-T showing more promise for solid tumors.
- Patient eligibility: CAR-T is broadly applicable. TCR-T is limited by HLA type.